Telitacicept alleviates IgA nephropathy by targeting PDHA1 lactylation to inhibit B cell metabolic reprogramming and lactate-mediated renal injury
Telitacicept confers renoprotection by inducing SIRT3-dependent PDHA1 delactylation to reverse metabolic reprogramming in IgAN. Targeting the PDHA1 lactylation-SIRT3 axis represents a novel therapeutic strategy for IgAN and related autoimmune disorders.
Authors
- Wenting Xu (ORCID: https://orcid.org/0000-0003-1175-912X)
- Jing-Jing Zhang
- Lu Xu
Institutions
- Anhui Medical University (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2026-03-03
- DOI
- https://doi.org/10.1186/s40001-026-04175-5
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00